Century Therapeutics, Inc. (IPSC) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Century Therapeutics reported revenue of $109.2M, up 1556.8% from $6.6M the year before. Net income was -$9.6M (a -8.8% net margin), or -$0.14 per diluted share. Operating margin was -15.8%. Operating activities generated -$103.9M of cash, leaving -$104.7M of free cash flow. At fiscal year end, Century Therapeutics held $223.7M in total assets against $64.8M in total liabilities, including $61.9M of cash and equivalents.
Open the full interactive Century Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Century Therapeutics Key Stats
| Share Price | $1.38 |
|---|---|
| Market Cap | $284.0M |
| 52-Week Range | $0.47 – $2.94 |
| Shares Outstanding | 205.8 million (basic, 2026 Q2) |
Century Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $5.2M | $2.2M | $6.6M | $109.2M |
| Operating Income | -$94.9M | -$133.8M | -$146.5M | -$138.1M | -$17.3M |
| Pre-Tax Income | -$95.8M | -$130.8M | -$134.8M | -$124.8M | -$9.6M |
| Income Tax | $43,000 | $91,000 | $1.9M | $1.8M | -$68,000 |
| Net Income | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| Diluted EPS | -$2.96 | -$2.27 | -$2.27 | -$1.61 | -$0.14 |
Century Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$34.4M | -$19.2M | -$21.6M | -$34.5M |
| Diluted EPS | -$0.40 | -$0.22 | -$0.11 | -$0.17 |
Century Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $56.4M | $84.3M | $47.3M | $58.4M | $61.9M |
| Current Assets | $228.2M | $319.7M | $177.0M | $194.1M | $120.8M |
| Total Assets | $437.4M | $486.5M | $360.7M | $353.2M | $223.7M |
| Current Liabilities | $15.7M | $29.8M | $17.8M | $129.8M | $20.2M |
| Total Long-Term Debt | $9.9M | $10.2M | — | — | — |
| Total Liabilities | $41.1M | $183.8M | $175.9M | $191.9M | $64.8M |
| Shareholders' Equity | $396.2M | $302.7M | $184.8M | $161.4M | $158.9M |
Century Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$89.0M | $14.1M | -$88.3M | -$110.1M | -$103.9M |
| Cash From Investing | -$298.3M | -$13.1M | $61.1M | $47.5M | $107.5M |
| Cash From Financing | $417.8M | $27.2M | -$9.7M | $74.6M | $173,000 |
| Free Cash Flow | -$134.0M | -$16.6M | -$102.1M | -$110.3M | -$104.7M |
Figures from Century Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Century Therapeutics financials page for every line item.
Century Therapeutics Company Profile
| Ticker | IPSC |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Philadelphia, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001850119 |
Frequently Asked Questions
What was Century Therapeutics' revenue in fiscal 2025?
Century Therapeutics (IPSC) reported revenue of $109.2M for fiscal 2025.
What is Century Therapeutics' annual revenue history?
Century Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $5.2M; 2023: $2.2M; 2024: $6.6M; 2025: $109.2M.
What was Century Therapeutics' net income in fiscal 2025?
Century Therapeutics reported net income of -$9.6M for fiscal 2025.
What was Century Therapeutics' earnings per share (EPS) in fiscal 2025?
Century Therapeutics' diluted EPS was -$0.14 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Century Therapeutics generate in fiscal 2025?
Century Therapeutics generated -$104.7M of free cash flow in fiscal 2025.
What was Century Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Century Therapeutics reported revenue of $0.
How many shares of Century Therapeutics are outstanding?
Century Therapeutics reported a weighted average of 205.8 million basic shares outstanding in 2026 Q2.
What is Century Therapeutics' market cap?
Based on its latest closing price, Century Therapeutics (IPSC) has a market capitalization of about $284.0M.
When does Century Therapeutics' fiscal year end?
Century Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Century Therapeutics headquartered?
Century Therapeutics lists its business address in Philadelphia, Pennsylvania in its SEC filings.
Century Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →